Key data highlights from SPL026 Phase IIa trial – Dr. Carol Routledge
Our Chief Medical & Scientific Officer Dr Carol Routledge, discusses some of the key result highlights from our Phase IIa trial of SPL026, what these results could mean for a potential future treatment, and what we’ll seek to explore in later-stage clinical trials.